High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 801–900 of 960
Fibrose pulmonaire idiopathique
Crestani, B., Marchand-Adam, S., Taillé, C., Borie, R., & Danel, C. J. (2009) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(09)34185-x · Cited by 1
Costabel, U. (2013) · Der Pneumologe · doi:10.1007/s10405-012-0648-1 · Cited by 1
Self-citationTo Suppress the Radicals We Must Have Biomarkers of Oxidative Stress
Jenkins, G. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2311ed · Cited by 1
Neue pharmakologische Therapieoptionen der idiopathischen Lungenfibrose?
Gutjahr, K., & Gillissen, A. (2009) · Pneumologie · doi:10.1055/s-0029-1214953 · Cited by 1
Idiopathic Pulmonary Fibrosis and Other Idiopathic Interstitial Pneumonias
Costabel, U. (2008) · Elsevier eBooks · doi:10.1016/b978-032304825-5.10050-9 · Cited by 1
Self-citationClinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Jones, R. (2016) · Cited by 1
Differenzielle Therapie bei Lungenfibrosen
Markart, P., Seeger, W., & Günther, A. (2006) · Der Internist · doi:10.1007/s00108-006-1641-8 · Cited by 2
Thoughts on the Diagnosis and Management of Interstitial Lung Diseases
de Andrade, J. A. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e31805f6da0 · Cited by 1
Redox regulation in pulmonary fibrosis: towards therapeutic targets
Veith (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190524cv · Cited by 1
Mutations in Surfactant Protein C and Interstitial Lung Disease
Panos, R. J., & Bridges, J. P. (2010) · Humana Press eBooks · doi:10.1007/978-1-59745-384-4_6 · Cited by 1
Voeghtly, L. (2009) · D-Scholarship@Pitt (University of Pittsburgh)
N-Acetylcystein-Therapie enttäuscht
Gillissen, A. (2014) · Pneumo News · doi:10.1007/s15033-014-0013-7
Therapie der idiopathischen Lungenfibrose
Schreiber, J. (2014) · Der Pneumologe · doi:10.1007/s10405-014-0819-3
Myositis: When Weakness Can Kill
Gordon, P., & Lundberg, I. E. (2011) · Springer eBooks · doi:10.1007/978-0-85729-358-9_12
Родосская, Н. К. (2013) · Journal of Physiology and Pharmacology Advances · doi:10.5455/jppa.20130720012707
Fibrosis pulmonar idiopática. Con el blanco en la mira
Otaola, M. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Perfil de alterações cognitivas em pacientes com fibrose pulmonar idiopática
Areza‐Fegyveres, R. (2009) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2009.tde-22022010-162759
Regulation of liver X receptors by microRNA-155 in pulmonary fibrosis
Hasoo, M. K. (2013) · Enlighten: Theses (The University of Glasgow)
Dekhuijzen, R. P. N. (2008) · Wiley eBooks · doi:10.1002/9780470475973.ch21
Self-citationOrzechowski, K. (2008) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-17724
Interstitial lung disease in a female patient with rheumatoid arthritis
Averkieva, Y. V., Raskina, T. A., Степановна, М. О., Volykova, M. A., & Maslova, O. (2014) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2014-1-27-30
Armin, S. M., Reza, S. M., Ostadi, A., Mazloumi, Z., & Mohammad, S. (2014) · Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Kirmānshāh · doi:10.22110/jkums.v18i7.1743
Current and Emerging Treatment Options in Interstitial Lung Disease
Maher, T. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0770-0_14
Vannella, K. M. (2009) · Deep Blue (University of Michigan)
Update on New Treatments for Idiopathic Pulmonary Fibrosis
DeGrado, J. R., & Gilmore, J. F. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0076-8
Eastwood, P. R., Takahashi, K., Lee, P., & Maher, T. M. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.01927.x
CASO: paciente con fibrosis pulmonar idiopática (FPI) de presentación atípica
Boyeras, I., Boscio, V. D., Downey, D., Nally, C., Jünemann, A., Vujacich, P., Rossi, S., Pelosi, M. R., & Aguilera, A. (2012) · Revista americana de medicina respiratoria
Molecular targets and their regulation in systemic lupus erythematosus
Takasaki, Y. (2012) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.35.176
Triple Therapy in Idiopathic Pulmonary Fibrosis
Castillo, D., & Barril, S. (2014) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.08.010
Recent Topics in Treatment for Idiopathic Pulmonary Fibrosis
Azuma, A. (2006) · Nihon Ika Daigaku Igakkai Zasshi · doi:10.1272/manms.2.192
Diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Ancochea, J., & Valenzuela, C. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70481-x
Tino, G. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200608-154tt
Manejo general y extrahospitalario del paciente con patología intersticial pulmonar
Francés, M. M. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70188-8
Manejo general y extrahospitalario del paciente con enfermedad pulmonar intersticial
Gracia, F. D., & Ariño, A. S. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70198-0
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Spagnolo, P., & Luppi, F. (2013) · Clinical Investigation · doi:10.4155/cli.13.107
Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going
Luppi, F., Spagnolo, P., Cerri, S., Sgalla, G., & Richeldi, L. (2012) · Current Respiratory Care Reports · doi:10.1007/s13665-012-0030-0
“Of note, during the 48 weeks of the trial, almost 25 % of patients withdrew from the study, similar to the dropout rates seen in other trials [18, 19], which represents an intrinsic potential issue inherent to long-term trials in IPF.”
BackgroundResultLa fibrose pulmonaire idiopathique
Uzunhan, Y. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72538-8
Raghu, G. (2007) · CHEST Journal · doi:10.1016/s0012-3692(15)51308-1
Y a-t-il des progrès dans le traitement et la compréhension de la fibrose pulmonaire idiopathique ?
Uzunhan, Y., & Bonniaud, P. (2008) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(08)74084-1
Respiratory medicine: interstitial pneumonia, cystic fibrosis and pulmonary hypertension
Mulrennan, S. A., & Muers, M. F. (2006) · Medicine · doi:10.1053/j.mpmed.2006.10.001
Ancochea, J., Pérez, T. A., Gutiérrez, M. D. V. S., & Valenzuela, C. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70847-9
Treatment of idiopathic interstitial pneumonias
Corte, T. J., & Wells, A. U. (2009) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.3.1.81
Pneumopathies interstitielles diffuses et sarcoïdose
Macey, J. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70177-5
Neumonías intersticiales idiopáticas
de Miguel, E. B., de Tejada, J. A. G. R., Morales, C. J., & González, F. M. (2011) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(11)70061-8
An approach to interstitial lung disease in India
Pande, J. N. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
Clinical networks for ILD: casting light on diffuse lung shadows
Harrison, N., Johnson, N. M., & WILSHER, M. L. (2010) · Thorax · doi:10.1136/thx.2009.122135
Bosentan for the treatment of idiopathic pulmonary fibrosis
Antoniu, S. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.611
“Acetylcysteine given at high doses in IPF patients for 1 year as an add-on therapy to the conventional regimen (prednisone and azathioprine), unlike bosentan, significantly slowed deterioration of lung volumes and gas exchange but did not impact significantly on survival, and disease progression free survival was not…”
BackgroundVeränderungen der Körperzusammensetzung von COPD-Patienten
Marcu, C. (2009) · Publications of the UdS (Saarland University) · doi:10.22028/d291-21229
“Es ist jedoch fraglich, ob die Dosierung mit 1800 mg/d NAC bei Patienten mit COPD in einer prospektiven Studie geprüft wird [29].”
BackgroundEnfermedad pulmonar intersticial idiopática
Peña, V. S. (2010) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(10)70195-5
Drug therapy to prevent and diminish radiation injury of the lungs
Sycheva, M., & Грушина, Т. И. (2013) · PULMONOLOGIYA · doi:10.18093/0869-0189-2013-0-6-85-91
Rossi, G. P., & Agostini, C. (2009)
Interstitial Lung Disease in Older Patients
Antin-Ozerkis, D. E. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-727-3_11
Prednison, Azathioprin und N-Acetylcystein bei Lungenfibrose
Behr, J. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0623-x
Self-citationStudies on TGF-β family signalling in the diseased lung tissue
Leppäranta, O. (2012) · Helda - University of Helsinki Institutional Repository
Health Effects of Nanoparticles (Inhalation) from Medical Point of View/Type of Diseases
Baughman, R. P., & Pirożyński, M. (2009) · Springer eBooks · doi:10.1007/978-90-481-2632-3_10
Traitement médical de la fibrose pulmonaire idiopathique : de nouvelles perspectives
Bouvry, D., & Jouneau, S. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70619-6
High-Dose Acetylcysteine in Idiopathic Pulmonary Disease
Lewis, K. L. (2007) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70388-8
Fibrose pulmonaire idiopathique : une nouvelle ère, de nouveaux défis
Cottin, V. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.07.009
The Point on N-acetylcysteine in Idiopathic Pulmonary Fibrosis Treatment
L, R. E. R. (2014) · Journal of Palliative Care & Medicine · doi:10.4172/2165-7386.1000193
“Although NAC mono therapy’s effects on IPF weren’t demonstrated in the only study conducted in comparison with placebo [22], the same journal published another article which demonstrated a major efficacy of the NAC combined therapy [21].”
BackgroundResultActualités dans la prise en charge de la fibrose pulmonaire idiopathique
Cottin, V., Crestani, B., Prévôt, G., Valeyre, D., Traclet, J., & Borie, R. (2013) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(13)70362-8
Dr. Fernández-Fernández and Dr. Sesma reply
Fernández‐Fernández, F. J., & Sesma, P. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.111105
3. Clinical Practice of Interstitial Lung Disease
Nukiwa, T. (2009) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.98.2112
Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension
Huston, J., Hatton, N. D., & Ryan, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_3
Fibrosis pulmonar idiopática. Nuevas terapéuticas y evidencia científica
Espinosa, Á. C., & Ancochea, J. (2007)
10. Diagnosis and Treatment for Idiopathic Pulmonary Fibrosis
Homma, S. A. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.2418
3e Journée française de la fibrose pulmonaire idiopathique. 19 septembre 2014
Cottin, V., Crestani, B., Danel, C. J., Debray, M., Nunès, H., Poletti, V. E., Prévost, G., Vergnon, J.-M., Wallaert, B., & Cordier, J. F. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2015.06.002
Self-citationびまん性肺疾患:診断と治療の進歩 III.最近の話題 6.特発性肺線維症の新しい治療薬
安良太, 吾. (2006) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.95.1069
ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES
Ferrara, G., & Sköld, M. C. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814656337_0012
Pulmonary management of systemic sclerosis
Denton, C. P., & Ong, V. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00145-5
Idiopaatiline kopsufibroos – äsjane kannapööre ravistrateegias uute lootuste nimel
Altraja, A. (2013) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.11452
Idiopathische pulmonale fibrose; beschrijving van een Nederlands cohort
Barlo, N. P., van de Graaf, E. A., & Grutters, J. C. (2009)
Acute exacerbations of interstitial lung disease
Veltkamp, M., & Grutters, J. C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10001816
Pneumopathies interstitielles diffuses
Wémeau-Stervinou, L. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30078-1
Raghu, G., Rochwerg, B. N., Zhang, Y., Cuello‐García, C. A., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W., Homma, S. A., et al. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50373
“Wytyczne z 2011 roku uwzględniły jedno kontrolowane badanie randomizowane, które porównywało N-acetylocysteinę z placebo u pacjentów otrzymujących prednizon i azatioprynę [22].”
Self-citationVicary, G. W. (2016) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2589
INVITED REVIEW SERIES: PULMONARY FIBROSIS
Kolb, M. R. J., Cox, G., & Behr, J. (2009)
Self-citationEnsayo clínico controlado de N-acetilcisteína en fibrosis pulmonar idiopática
Matiz, C. E., & Riaño, D. (2014) · Revista Colombiana de Neumología · doi:10.30789/rcneumologia.v26.n4.2014.2
Tratamiento de la fibrosis pulmonar idiopática
Matiz, C. E. (2016) · Revista Colombiana de Neumología · doi:10.30789/rcneumologia.v26.n4.2014.1
Acetylcysteine in IPF: the knockout blow?
Norris, L. (2016)
Novel approaches to identify biomechanisms in systemic sclerosis
Lopez, H. (2017) · UCL Discovery (University College London)
Idiopathic Pulmonary Fibrosis: Treatment Strategies
Varela, B. E., & Tabaj, G. C. (2015) · Clinical Anti-Inflammatory & Anti-Allergy Drugs · doi:10.2174/221270380102150520112938
Traitement de la fibrose pulmonaire idiopathique : un espoir pour les connectivites
Wémeau-Stervinou, L., Chenivesse, C., & Wallaert, B. (2018) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2018.03.003
Self-citationTherapeutic approach and molecular targets for novel treatments
Sgalla, G., Jones, M. G., & Richeldi, L. (2015) · doi:10.2217/fmeb2013.14.74
Diffuse Parenchymal Lung Diseases in the Elderly
Walsh, S. M., & O'Regan, A. W. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0249-x
Souza, R. M. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-05082019-115728
Biswas, M. A., Islam, M. N., Walid, K. M., & Rassel, Z. Z. (2019) · Faridpur Medical College Journal · doi:10.3329/fmcj.v13i2.43646
Idiopathic Pulmonary Fibrosis-Treatment and Management
Collins, B. F., & Raghu, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11455-2
Redox mechanisms in pulmonary disease: Emphasis on pulmonary fibrosis
Janssen-Heininger, Y. M. W., & Anathy, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-818606-0.00035-3 · Cited by 1
Pneumopathies interstitielles diffuses
Nunès, H., & Uzunhan, Y. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72742-9
Erkrankungen der Atmungsorgane
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50007-8
Fischer, A., & du Bois, R. M. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-374994-9.10045-2
Pneumopathies interstitielles diffuses
Nunès, H. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)72016-2
Idiopathische interstitielle Lungenerkrankungen
Costabel, U. (2007) · Elsevier eBooks · doi:10.1016/b978-3-437-22136-1.50007-3
Self-citationSiregar, S. S., Salim, E. M., Hafy, Z., Kurniati, N., Hudari, H., Bahar, E., Putra, A. D., & Siregar, A. (2021) · Jurnal Kedokteran dan Kesehatan Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya · doi:10.32539/jkk.v8i2.174
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.